Caliper Life Sciences IVIS Lumina II imaging system

描述(由申请人提供)：华盛顿大学医学中心寻求收购卡利珀生命科学IVIS(R)Lumina II成像系统，这将为我们的无特定病原体(SPF)ABSL-2动物设施提供新的实验技术。该仪器利用超灵敏的相机检测活体动物体内的生物发光和荧光记者，使用户能够收集解剖定位的纵向数据 关于细胞特异性命运、基因表达和复制感染的动力学和分布 个体活体动物体内的代理人，而不需要安乐死。这一系统极大地增加了可以从单个动物身上收集的数据量，并减少了每次实验所需的动物数量。这项技术为数据集增加了时间维度，这是对实验的有力补充，再加上仪器能够解释老鼠对刺激的反应的个体差异，即使是在遗传相同的近交系之间。收购IVIS(R)Lumina II对于华盛顿大学保持其高质量的研究和生产力水平以及 促进由美国国立卫生研究院资助的微生物学、实验室医学、病理学、全球健康和过敏/传染病系内的几个实验室开展的研究计划的扩展。这些实验室在宿主-病原体相互作用方面有着共同的兴趣。利用人类疾病的啮齿动物模型，研究人员将使用这种成像系统在体内监测传染病、免疫和炎症反应，以及基因调控。这些研究领域中的每一个都与公共卫生高度相关，增强了我们对恶性肿瘤、炎症性肠病和对全球健康具有重要意义的传染病的理解。将使用这种活体成像系统的动物研究小组由六个主要用户(库克森、克里斯佩、史密斯、方、霍恩和斯克雷特)组成。主要用户是大量研究生和医学培训计划中的教师，这些计划支持对不断增长的研究生和博士后研究员的培训深度和广度。我们预计，这项独特而强大的技术在华盛顿大学医学院的集中位置将吸引动物研究社区的新用户，其中包括使用IACUC批准的方案的400多个教职员工。收购卡利珀生命科学IVIS(R)Lumina II成像系统将通过对动物模型系统的研究培养对人类疾病的新见解，并促进我们对人类疾病的理解、诊断和治疗。 与公共健康相关：IVIS(R)Lumina II使用超灵敏相机来探测报告基因发出的光，并将提供有关活动物的细胞活动、基因表达、炎症和感染的解剖定位信息。重要的是，这些活动的时间方面也被揭示出来。因此，这项应用中的研究将提供有关癌症、感染和自身免疫性疾病等重要问题的重要诊断和潜在治疗信息。

DESCRIPTION (provided by applicant): The University of Washington Medical Center seeks the acquisition of a Caliper Life Sciences IVIS(R) Lumina II Imaging System, which will provide new experimental technology for our specific pathogen free (SPF) ABSL-2 animal facility. This instrument utilizes an ultrasensitive camera to detect both bioluminescent and fluorescent reporters within living animals, allowing users to collect anatomically localized longitudinal data on cell-specific fates, gene expression and the kinetics and distribution of replicating infectious agents within individual living animals without the need for euthanasia. This system dramatically increases the amount of data that can be collected from individual animals and reduces the number of animals required for each experiment. This technology adds the dimension of time to data sets, which is a powerful addition to experiments when coupled with the ability of the instrument to account for individual mouse variation in response to stimuli, even among genetically identical inbred strains. The acquisition of an IVIS(R) Lumina II is essential for the University of Washington to maintain its high quality of research and level of productivity, and to facilitate the expansion of the research programs carried out by several NIH-funded laboratories within the Departments of Microbiology, Laboratory Medicine, Pathology, Global Health, and Allergy/Infectious Disease. These laboratories share a common interest in host-pathogen interactions. Using rodent models of human disease, researchers will use this imaging system for in vivo monitoring of infectious diseases, immune and inflammatory responses, and gene regulation. Each of these fields of research is highly relevant to public health, enhancing our understanding of malignancy, inflammatory bowel disease, and infectious diseases of significance for global health. The animal research group that will use this in vivo imaging system consists of six major users (Cookson, Crispe, Smith, Fang, Hawn, and Skerrett). The major users are faculty within a large number of graduate and medical training programs, which support the training of an ever-increasing depth and breadth of graduate students and post-doctoral fellows. We anticipate that the centralized location of this unique and powerful technology at the University Of Washington School Of Medicine will attract new users within the animal research community, which includes over 400 faculties with IACUC approved protocols. Acquisition of the Caliper Life Sciences IVIS(R) Lumina II Imaging System will foster novel insight into human disease through the study of model animal systems, and advance our understanding, diagnosis and treatment of human diseases. PUBLIC HEALTH RELEVANCE: The IVIS(r) Lumina II uses an ultrasensitive camera to detect light from reporter genes and will provide anatomically localized information about cellular activities, gene expression, inflammation and infection in living animals. Importantly, the temporal aspects of these activities are also revealed. Thus, important diagnostic and potentially therapeutic information about important problems such as cancer, infection and autoimmune diseases will be provided from the studies in this application.